Search results

124 results

Sorted by Date . Sort by Relevance

  1. Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)

    Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children

  2. Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers (MTG20)

    Evidence-based recommendations on Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers

  3. The ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury (MTG21)

    Evidence-based recommendations on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury

  4. Safe staffing for nursing in adult inpatient wards in acute hospitals (SG1)

    This guideline covers organisational and managerial approaches to safe nurse staffing of inpatient wards for people aged 18 and over in acute hospitals. It aims to ensure that patients receive the nursing care they need, regardless of the ward to which they are allocated, the time of the day, or the day of the week.

  5. The MAGEC system for spinal lengthening in children with scoliosis (MTG18)

     April 2020: This guidance has been withdrawn while the MHRA conducts an investigation into the MAGEC system. The MHRA issued a Medical Device Alert MDA/2020/011 for all MAGEC systems. This is in response to the manufacturer’s latest Field Safety Notice and previous field safety notices for problems that may require early removal of devices and lead to inadequate treatment. The MHRA is not recommending prophylactic removal of devices but the supply of all MAGEC systems is suspended in the UK while the MHRA investigation is ongoing. The MHRA has set out the following actions: Do not implant MAGEC rods in the UK until further notice. Identify all patients implanted with a MAGEC System and ensure systems are in place to follow up these patients.

  6. WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension (MTG13)

    Evidence-based recommendations on the WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension

  7. BRAHMS copeptin assay to rule out myocardial infarction in patients with acute chest pain (MTG4)

    In November 2016, NICE reviewed this guidance and recommended that it should be withdrawn. The guidance was published in June 2011 and recommended that further research was carried out on the technology. There was insufficient evidence on its use in clinical practice to recommend adoption. On reviewing the guidance in 2016, NICE determined that: The comparator in the original guidance, standard serial troponin testing, was changed in 2014 to high sensitivity troponin testing which expert advice indicated is now widespread in the NHS The clinical pathway in the original evaluation has significantly changed and the original scope is no longer valid. These changes mean that the current guidance is no longer valid and NICE would not be able to update it. The guidance has therefore been withdrawn. For a copy of the review decision please contact nice@nice.org.uk.

  8. Improving outcomes for people with sarcoma (CSG9)

    This guideline covers how healthcare services for people with sarcoma should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.

  9. Improving outcomes in children and young people with cancer (CSG7)

    This guideline covers how healthcare services for children and young people with cancer should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.

  10. Improving outcomes in head and neck cancers (CSG6)

    This guideline covers how healthcare services for adults with head and neck cancers should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.

  11. Improving supportive and palliative care for adults with cancer (CSG4)

    This guideline covers best practice in developing and delivering cancer services for adults. It aims to ensure that people with cancer, and their families and carers, are well informed, cared for and supported from before formal diagnosis onward.

  12. Improving outcomes in urological cancers (CSG2)

    This guideline covers how healthcare services for people with urological cancer should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.

  13. Improving outcomes in breast cancer (CSG1)

    This guideline covers how healthcare services for breast cancer should be organised. It aims to improve care for women with breast cancer by recommending which healthcare professionals should be involved in care.